Pfizer announced small variations in the original COVID-19 virus and mutant strains are unlikely to lower their vaccines’ effectiveness. The news comes after suggestions that the pharmaceutical giant’s supply would not be fully effective in battling the new virus variants that recently emerged from the UK and South Africa.
“The small differences in viral neutralisation observed in these studies are unlikely to lead to a significant reduction in the effectiveness of the vaccine,” Pfizer and BioNTech said in response to results from a new vaccine study.
